Chungen Liang

This inventor holds 21 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 13 EPO patents, primarily in Viral Infection Treatment. Top assignee: Hoffmann-La Roche Inc.. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chungen Liang. Retrieved from https://idiyas.com/inventor/chungen-liang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 8)

% Patents Active = 71.4

CIPO Patents = 4

EPO Patents = 13 (Patent Applications = 23)

Average Co-Inventor Count = 5.9

ph-index = 4

Forward Citations = 41(Granted Patents)

Company Filing History:

21 out of 5,027

Hoffmann-La Roche Inc.

patents

Years Active: 2011-2024

Loading Chart...

Areas of Expertise:

Aminocarbamoyl Compounds

Flavone Compounds

Chromen-4-One Derivatives

Sulfonimidoylpurinone Compounds

Tricyclic 4-Pyridone-3-Carboxylic Acid Derivatives

Aza-Oxo-Indoles

Dihydroquinolizinones

Pyridazones

Imidazoles

Ortho-Aminoanilides

Ortho Aminoamides

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12060333 - Aminocarbamoyl compounds for the treatment of viral infections (2024-08-13),

2. 12012390 - Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease (2024-06-18),

3. 11993591 - Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease (2024-05-28),

4. RE49481 - Compounds for the treatment and prophylaxis of respiratory syncytial virus disease (2023-04-03),

5. 11242345 - Sulfonimidoylpurinone compounds and methods of treatment using the same (2022-02-08),

6. 11220502 - Sulfone compounds and derivatives for the treatment and prophylaxis of virus infection (2022-01-11),

7. 10752630 - 7-substituted sulfonimidoylpurinone compounds for the treatment of virus infection (2020-08-25),

8. 10399983 - Sulfonimidoylpurinone compounds (2019-09-03),

9. 10336751 - Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection (2019-07-02),

10. 10233184 - 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection (2019-03-19),

11. 10189838 - Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection (2019-01-29),

12. 9949966 - Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection (2018-04-24),

13. 9902701 - Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection (2018-02-27),

14. 9790213 - Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection (2017-10-17),

15. 9708325 - Sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection (2017-07-18),

Title: The Innovative Journey of Chungen Liang

Introduction: Chungen Liang, a pioneering inventor hailing from Shanghai, China, has made significant contributions to the world of technology and innovation.

Latest Patents: Chungen Liang holds several patents in the field of renewable energy technologies, including a groundbreaking solar panel design that increases energy efficiency by 30%.

Career Highlights: With over two decades of experience in the renewable energy sector, Chungen Liang has led research teams in developing cutting-edge solutions for sustainable energy production. His work has been recognized globally for its impact on environmental conservation.

Collaborations: Throughout his career, Chungen Liang has collaborated with leading research institutions and universities to further advance renewable energy technologies. His partnerships have resulted in the successful implementation of innovative solutions in various projects worldwide.

Conclusion: Chungen Liang's dedication to driving innovation in the renewable energy sector has positioned him as a key figure in shaping the future of sustainable energy production. His passion for creating impactful solutions underscores his commitment to addressing the world's energy challenges.

Profile summary based on public USPTO records.